

P504S (P)

Concentrated and Prediluted Polyclonal Antibody
902-200-022522

BIOCARE
M E D I C A L

| Available Product Formats | | | | |
|------------------------------|----------------|------------------|--------------|---------------------------------|
| Format | Catalog Number | Description | Dilution | Diluent |
| Concentrate | CP 200 A, B, C | 0.1, 0.5, 1.0 mL | 1:100 | Renaissance Background Reducing |
| Predilute | PP 200 AA, H | 6.0, 25 mL | Ready-to-use | N/A |
| intelliPATH FLX | IPR 200 G10 | 10 mL | Ready-to-use | N/A |
| UltraLine – For BenchMark | VP 200R G, G25 | 6.0, 25 mL | Ready-to-use | N/A |
| Q Series– For Leica BOND-III | ALR 200 G7 | 7.0 mL | Ready-to-use | N/A |

Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

Summary and Explanation:

P504S, also known as α -methylacyl coenzyme A racemase (AMACR), is a peroxisomal and mitochondrial enzyme that plays a role in bile acid synthesis and β -oxidation of branched chain fatty acids (1). *P504S* was initially identified from a cDNA library as a gene that is overexpressed in human prostate cancer; with little or no expression in normal prostate (2,3). In immunohistochemistry, P504S has been shown to be a specific marker of prostatic adenocarcinoma (2-5). Additionally, prostate glands involved in PIN have been found to express P504S, whereas P504S was nearly undetectable in benign glands (5,6).

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

Source: Rabbit polyclonal

Species Reactivity: Human; others not tested

Clone: N/A

Isotype: IgG

Protein Concentration: Call for lot specific Ig concentration.

Epitope/Antigen: P504S

Cellular Localization: Granular and cytoplasmic

Positive Tissue Control: Prostate cancer

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Staining Protocol Recommendations (intelliPATH FLX® and manual use):

Peroxide Block: Block for 5 minutes with Peroxidized 1.

Pretreatment: Perform heat retrieval using Reveal Decloaker. Refer to the Reveal Decloaker product data sheet for specific instructions:

Protein Block (Optional): Incubate for 5-10 minutes at RT with Background Punisher.

Primary Antibody: Incubate for 30 minutes at RT.

Probe: N/A

Polymer: Incubate for 30 minutes at RT with a secondary-conjugated polymer.

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

Counterstain: Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Staining Protocol Recommendations (intelliPATH FLX and manual use) Cont'd:

intelliPATH FLX Automated Slide Stainer:

IPR200 is intended for use with the intelliPATH FLX. Refer to the User Manual for specific instructions for use. When using the intelliPATH FLX, peroxide block with intelliPATH FLX Peroxidase Blocking Reagent (IPB5000) may be performed following pretreatment.

Technical Note:

This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

Staining Protocol Recommendations (Ventana BenchMark ULTRA):

VP200R is intended for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

- Using **ultraView on XT/ULTRA:**

Template/Detection: ultraView DAB

Pretreatment Protocol: CC1 Standard

Primary Antibody: 32 minutes, 37°C

ultraBlock (V-Blocker BRI4001): Incubate for 4 minutes (with appropriate Option # registered by user)

V-Blocker is recommended to be applied prior to any detection system.

- Using **OptiView on ULTRA:**

Template/Detection: OptiView DAB IHC

Pretreatment Protocol: CC1 32 minutes

Peroxidase: Pre-Primary Peroxidase Inhibitor

Primary Antibody: 16 minutes, 36°C

Staining Protocol Recommendations (Q Series – For Leica BOND-III):

ALR200 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

Protocol Name: IHC Protocol F Delayed Peroxidase

Detection: Bond Polymer Refine

HIER: 20 min with ER1

Marker (Primary Antibody): 15 min

Post Primary: 8 min

Polymer: 8 min

Peroxide Block: 5 min

Mixed DAB Refine: 10 min

Hematoxylin: 5 min

Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide



60 Berry Drive
Pacheco, CA 94553
USA

TP v1 (10/26/2021)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

P504S (P)

Concentrated and Prediluted Polyclonal Antibody
902-200-022522

BIOCARE
M E D I C A L

Precautions Cont'd:

build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (7)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (8)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

Technical Support:

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.

References:

1. Ferdinandusse S, *et al.* Subcellular localization and physiological role of α -methylacyl-CoA racemase. *J Lipid Res.* 2000; 41:1890-6.

2. Xu J, *et al.* Identification of Differentially Expressed Genes in Human Prostate Cancer Using Subtraction and Microarray. *Cancer Res.* 2000; 60:1677-82.

3. Rubin MA, *et al.* α -Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. *JAMA.* 2002; 287:1662-70.

4. Luo J, *et al.* Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. *Cancer Res.* 2002; 62:2220-6.

5. Zhou M, *et al.* Alpha-Methylacyl-CoA Racemase A Novel Tumor Marker Overexpressed in Several Human Cancers and Their Precursor Lesions. *Am J Surg Pathol.* 2002; 26:926-31.

6. Wu CL, *et al.* Analysis of α -Methylacyl-CoA Racemase (P504S) Expression in High-Grade Prostatic Intraepithelial Neoplasia. *Hum Pathol.* 2004; 35:1008-13.

7. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."

8. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Ultraline antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.



Biocare Medical

60 Berry Drive

Pacheco, CA 94553

USA

TP v1 (10/26/2021)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080